Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer

Genetic Testing

Volumn 9, Issue 1, 2005, Pages 48-53

  Peters, Nikki ^a   Domcheck, Susan M ^a,b   Rose, Abigail ^a   Polis, Rachael ^a   Stopfer, Jill ^a,b   Armstrong, Katrina ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c 1204 Blockley Hall ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; ATTITUDE; AWARENESS; BREAST CANCER; COLLEGE; CONTROLLED STUDY; EDUCATION; FAMILY; FEMALE; GENETIC PROCEDURES; HEALTH CARE COST; HUMAN; MEDICAL DECISION MAKING; QUESTIONNAIRE; SUPPORT GROUP;

ADULT; AGE OF ONSET; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC SCREENING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MIDDLE AGED; QUESTIONNAIRES;

EID: 17844395471     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/gte.2005.9.48     Document Type: Article

References (32)

1. AMERICAN SOCIETY OF CLINICAL ONCOLOGY. (2003). American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J. Clin. Oncol. 21, 2397-2406.
2. ARMSTRONG, K., CALZONE, K., STOPFER, J., et al. (2000). Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol. Biomarkers Prev. 9, 1251-1254.
3. ARMSTRONG, K., WEBER, B., FITZGERALD, G., et al. (2003). Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination. Am. J. Med. Genet. 120, 359-364.
4. CAPPELLI, M., SURH, L., HUMPHREYS, L., et al. (1999). Psychological and social determinants of women's decisions to undergo genetic counseling and testing for breast cancer. Clin. Genet. 55, 419-430.
5. CARTER, C.L., SCOTT, J.A., GLAUBER, P.M., et al. (1997). The Oncormed approach to genetic testing. Genet. Test. 1, 137-144.
6. COUCH, F., DESHANO, M., BLACKWOOD, M., et al. (1997). BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N. Engl. J. Med. 336, 1409-1415.
7. DE SANJOSE, S., LEONE, M., BEREZ, V., et al. (2003). Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int. J. Cancer 106, 588-593.
8. DOMCHEK, S., EISEN, A., CALZONE, K., et al. (2003). Application of breast cancer risk prediction models in clinical practice. J. Clin. Oncol. 21, 593-601.
9. FORD, D., and EASTON, D.F. (1995). The genetics of breast and ovarian cancer. Br. J. Cancer 72, 805-812.
10. GARBER, J. (1999). A 40-year-old woman with a strong family history of breast cancer. J. Am. Med. Assn. 282, 1953-1960.
11. HARTMANN, L.C., SELLERS, T.A., SCHAID, D.J., et al. (2001). Efficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers. J. Natl. Cancer Inst. 93, 1633-1637. http://www.cms.hhs.gov/mcd/viewlmrp.asp? lmrp_id=9741&lmrp_version=5&show=all (accessed December 15, 2004).
12. HUGHES, C., GOMEZ-CAMINERO, A., BENKENDORF, J., et al. (1997). Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. Patient Educ. Couns. 32, 51-62.
13. KAUFF, N.D., SATAGOPAN, J.M., ROBSON, M.E., et al. (2002). Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 346, 1609-1516.
14. KINNEY, A.Y., CROYLE, R.T., DUDLEY, W.N., et al. (2001). Knowledge, attitudes, and interest in breast-ovarian cancer gene testing: a survey of a large African-American kindred with a BRCA1 mutation. Prev. Med. 33, 543-551.
15. LANGSTON, A.A., MALONE, K.E., THOMPSON, J.D., et al. (1996). BRCA1 mutations in a population-based sample of young women with breast cancer. N. Engl. J. Med. 334, 137-142.
16. LERMAN, C., NAROD, S., SCHULMAN, K., et al. (1996). BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes. J. Am. Med. Assn. 275, 1885-1889.
17. LERMAN, C., HUGHES, C., BENKENDORF, J.L., et al. (1999). Racial differences in testing motivation and psychological distress following pretest education for BRCA1 gene testing. Cancer Epidemiol. Biomarkers Prev. 8, 361-367.
18. LOMAN, N., JOHANNSSON, O., KRISTOFFERSSON, U., et al. (2001). Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J. Natl. Cancer Inst. 93, 1215-1223.
19. MALONE, K., DALING, J., THOMPSON, J., et al. (1998). BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. J. Am. Med. Assn. 279, 922-929.
20. MEIJERS-HEIJBOER, H., VAN GEEL, B., VAN PUTTEN, W.L., et al. (2001). Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 345, 159-164.
21. MEISER, B., BUTOW, P., BARRATT, A., et al. (2000). Attitudes to genetic testing for breast cancer susceptibility in women at increased risk developing hereditary breast cancer. J. Med. Genet. 37, 472-476.
22. MOGILNER, A., OTTEN, M., CUNNINGHAM, J.D., et al. (1998) Awareness and attitudes concerning BRCA gene testing. Ann. Surg. Oncol. 5, 607-612.
23. MYRIAD GENETIC LABORATORIES, INC. Services and Price list. Effective 2/15/2004. Available from http://www.myriad.com.
24. NEUHAUSEN, S.L., and OSTRANDER E.A. (1997). Mutation testing of early onset breast cancer genes BRCA1 and BRCA2. Genet. Test. 1, 75-83.
25. PETERS, N., ROSE, A., and ARMSTRONG, K. (2004). The association between race and attitudes about predictive genetic testing. Cancer Epidemiol Biomarkers Prev. 13, 361-365.
26. PETERSON E.A., MILLIRON, K.J., LEWIS, K.E., et al. (2002). Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol., Biomarkers & Prevent. 11, 79-87.
27. PETO, J., COLLINS, N., BARFOOT, R., et al. (1999). Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J. Natl. Cancer Inst. 91, 943-949.
28. REBBECK, T.R., LYNCH, H.T., NEUHAUSEN, S.L., et al. (2002). Prevention and observation of surgical end points study group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616-1622.
29. REBBECK, T.R., FRIEBEL, T., LYNCH, H.T., et al. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J. Clin. Oncol. 22, 1055-1062.
30. SCHRAG, D., KUNTZ, K.M., GARBER, J.E., et al. (2000). Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. J. Am. Med. Assn. 283, 617-624.
31. STRUEWING, J.P., LERMAN, C., KASE, R.G., et al. (1995). Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. Cancer Epid. Biomarkers Prev. 4, 169-173.
32. WARNER, E., PLEWES, D.B., SHUMAK, R.S., et al. (2001). Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J. Clin. Oncol. 19, 3524-3531.